Cargando…

Cetrorelix in reproductive medicine

This book chapter presents the most important clinical aspects concerning the gonadotropin-releasing hormone antagonist cetrorelix and its importance in reproductive medicine. After an overview of the historical milestones in the development and establishment of cetrorelix in the context of ovarian...

Descripción completa

Detalles Bibliográficos
Autores principales: Findeklee, Sebastian, Diedrich, Prof Klaus
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10201282/
https://www.ncbi.nlm.nih.gov/pubmed/37223762
http://dx.doi.org/10.1016/j.xfre.2022.11.012
_version_ 1785045233508024320
author Findeklee, Sebastian
Diedrich, Prof Klaus
author_facet Findeklee, Sebastian
Diedrich, Prof Klaus
author_sort Findeklee, Sebastian
collection PubMed
description This book chapter presents the most important clinical aspects concerning the gonadotropin-releasing hormone antagonist cetrorelix and its importance in reproductive medicine. After an overview of the historical milestones in the development and establishment of cetrorelix in the context of ovarian stimulation treatment, its dosage, effects, and side effects are evaluated. The chapter terminates with a conclusion emphasizing the ease of use and the increase in patient safety because of a significantly reduced risk of ovarian hyperstimulation syndrome with cetrorelix compared with the agonist protocol
format Online
Article
Text
id pubmed-10201282
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Elsevier
record_format MEDLINE/PubMed
spelling pubmed-102012822023-05-23 Cetrorelix in reproductive medicine Findeklee, Sebastian Diedrich, Prof Klaus F S Rep Special Issue This book chapter presents the most important clinical aspects concerning the gonadotropin-releasing hormone antagonist cetrorelix and its importance in reproductive medicine. After an overview of the historical milestones in the development and establishment of cetrorelix in the context of ovarian stimulation treatment, its dosage, effects, and side effects are evaluated. The chapter terminates with a conclusion emphasizing the ease of use and the increase in patient safety because of a significantly reduced risk of ovarian hyperstimulation syndrome with cetrorelix compared with the agonist protocol Elsevier 2022-11-21 /pmc/articles/PMC10201282/ /pubmed/37223762 http://dx.doi.org/10.1016/j.xfre.2022.11.012 Text en © 2022 The Authors https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Special Issue
Findeklee, Sebastian
Diedrich, Prof Klaus
Cetrorelix in reproductive medicine
title Cetrorelix in reproductive medicine
title_full Cetrorelix in reproductive medicine
title_fullStr Cetrorelix in reproductive medicine
title_full_unstemmed Cetrorelix in reproductive medicine
title_short Cetrorelix in reproductive medicine
title_sort cetrorelix in reproductive medicine
topic Special Issue
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10201282/
https://www.ncbi.nlm.nih.gov/pubmed/37223762
http://dx.doi.org/10.1016/j.xfre.2022.11.012
work_keys_str_mv AT findekleesebastian cetrorelixinreproductivemedicine
AT diedrichprofklaus cetrorelixinreproductivemedicine